Please assess the completion status of the following clinical trial:

Trial Title: Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Includes:~* The participant has a documented diagnosis of type 1 Gaucher disease, as determined by deficient glucocerebrosidase (GCB) activity relative to normal as measured in leukocytes or by genotype analysis and the participant/legal guardian is willing and able to provide written informed consent prior to initiating any study-related procedures~* The participant has received consistent treatment with imiglucerase at a dose ≤ 60 U/kg and ≥ 15 U/kg every other week for a minimum of 30 consecutive months. Participants who are anti-imiglucerase antibody positive will be allowed to enter this study~* The participant is at least 2 years of age~* Female participants of child-bearing potential agree to use a medically acceptable method of contraception. Male participants must agree to use a medically acceptable method of birth control~* Participant must be sufficiently co-operative to participate in the study as judged by the Investigator.~Exclusion Criteria:~Includes:~* The participant has type 2 or 3 Gaucher disease or is suspected of having type 3 Gaucher disease~* The participant has received treatment with any investigational drug or device within the 30 days prior to study entry; such use during the study is not permitted~* Participant is HIV positive~* Participant is hepatitis B/C positive~* The participant presents with sustained iron, folic acid and/or vitamin B12 deficiency-related anemia during Screening~* The participant, participant's parent(s), or participant's legal guardian(s) is/are unable to understand the nature, scope, and possible consequences of the study~* The participant has a significant comorbidity that might affect study data or confound the study results~* The participant is unable to comply with the protocol or is otherwise unlikely to complete the study, as determined by the Investigator~* The participant has experienced an anaphylactic/anaphylactoid reaction during treatment with imiglucerase~* The participant has received miglustat during the 6 months prior to study enrollment~* The participant has an active, clinically significant spleen infarction~* The participant has active, progressive bone necrosis~* The participant is a pregnant and/or lactating female

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GA-GCB (velaglucerase alfa) (Type: EXPERIMENTAL): 15-60 U/kg, every other week via intravenous infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).